Table 3.
Hazard ratio (HR) and 95% confidence interval (95 %CI) between vaccination and the risk of hospitalization for COVID-19 and related risk reduction by windows of follow-up, stratified by age and sex. Adjustment for region, type of residence and other variables of Table 1 (including comorbidities) using inverse probability of treatment weighting.
| Age | Less than 85 years | 85 years or older | ||
|---|---|---|---|---|
| Population | Unvaccinated | Vaccinated | Unvaccinated | Vaccinated |
| Follow-up after the 1st dose | ||||
| Number of events/at-risk population | 3,604/1,781,722 | 667/949,480 | 2,976/849,386 | 796/472,981 |
| HR (95 %CI) | 1 | 0.34 (0.32–0.37) | 1 | 0.47 (0.43–0.50) |
| Follow-up from 1st dose to day 13 | ||||
| Number of events/at-risk population | 1,440/1,781,722 | 324/949,480 | 1,355/849,386 | 361/472,981 |
| HR (95 %CI) | 1 | 0.42 (0.37–0.47) | 1 | 0.48 (0.42–0.54) |
| Follow-up from day 14 after the 1st dose to the 2nd dose | ||||
| Number of events/at-risk population | 942/1,467,684 | 281/788,082 | 674/624,065 | 313/357,772 |
| HR (95 %CI) | 1 | 0.55 (0.48–0.63) | 1 | 0.81 (0.70–0.92) |
| Follow-up after the 2nd dose | ||||
| Number of events/at-risk population | 1213/1,191,877 | 58/644,505 | 929/500,990 | 117/291,482 |
| HR (95 %CI) | 1 | 0.09 (0.07–0.11) | 1 | 0.21 (0.17–0.25) |
| Follow-up from day 7 after the 2nd dose | ||||
| Number of events/at-risk population | 797/1,062,152 | 42/576,800 | 609/449,476 | 71/263,746 |
| HR (95 %CI) | 1 | 0.10 (0.07–0.13) | 1 | 0.19 (0.15–0.25) |
| Sex |
Women |
Men |
||
| Population | Unvaccinated | Vaccinated | Unvaccinated | Vaccinated |
| Follow-up after the 1st dose | ||||
| Number of events/at-risk population | 3,230/1,537,209 | 693/820,274 | 3,350/1,093,899 | 770/602,187 |
| HR (95 %CI) | 1 | 0.39 (0.36–0.43) | 1 | 0.41 (0.37–0.44) |
| Follow-up from 1st dose to day 13 | ||||
| Number of events/at-risk population | 1,400/1,537,209 | 317/820,274 | 1,395/1,093,899 | 368/602,187 |
| HR (95 %CI) | 1 | 0.42 (0.37–0.48) | 1 | 0.48 (0.42–0.53) |
| Follow-up from day 14 after the 1st dose to the 2nd dose | ||||
| Number of events/at-risk population | 754/1,207,043 | 295/652,050 | 862/884,706 | 299/493,804 |
| HR (95 %CI) | 1 | 0.71 (0.62–0.81) | 1 | 0.61 (0.54–0.70) |
| Follow-up after the 2nd dose | ||||
| Number of events/at-risk population | 1057/977,385 | 76/532,282 | 1085/715,482 | 99/403,705 |
| HR (95 %CI) | 1 | 0.13 (0.10–0.16) | 1 | 0.15 (0.12–0.19) |
| Follow-up from day 7 after the 2nd dose | ||||
| Number of events/at-risk population | 696/855,009 | 48/468,481 | 710/624,069 | 65/354,859 |
| HR (95 %CI) | 1 | 0.12 (0.09–0.16) | 1 | 0.16 (0.12–0.20) |